NovoCure Limited - SIC # 3840 -

Ticker Exchange SIC # Website Latest Ticker
NVCR Nasdaq 3840 www.novocure.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for NovoCure Limited

Strong week for NovoCure (NASDAQ:NVCR) shareholders doesn't alleviate pain of three-year loss - Jun 30th, 2025 8:53 am
NovoCure (NVCR) Soars 5.3%: Is Further Upside Left in the Stock? - Jun 30th, 2025 7:32 am
Novocure to Report Second Quarter 2025 Financial Results - Jun 30th, 2025 5:00 am
What Makes NovoCure (NVCR) a New Buy Stock - Jun 18th, 2025 10:00 am
NVCR Stock Dips Despite Positive OS Data From Phase 3 PANOVA-3 Trial - Jun 6th, 2025 10:26 am
NovoCure's Tumor Treating Fields Boost One-Year And Pain-Free Survival In Pancreatic Cancer Trial - Jun 2nd, 2025 12:05 pm
Results From the Phase 3 PANOVA-3 Trial of Novocure’s Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting - May 31st, 2025 6:00 am
1 Stock Down 35% This Year You'll Regret Not Buying on the Dip, According to Wall Street - May 28th, 2025 4:57 am
Novocure Announces Upcoming Investor Events - May 27th, 2025 5:00 am
The Next Frontier to Treat Cancer: Electricity - May 16th, 2025 8:00 am
Does NovoCure (NVCR) Have the Potential to Rally 105.5% as Wall Street Analysts Expect? - May 15th, 2025 7:55 am
Wall Street Analysts See a 91.92% Upside in NovoCure (NVCR): Can the Stock Really Move This High? - Apr 29th, 2025 7:55 am
Why NovoCure Stock Skyrocketed This Week - Apr 25th, 2025 11:21 am
Why NovoCure Stock Leaped 4% Higher Today - Apr 24th, 2025 5:03 pm
NovoCure (NVCR) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates - Apr 24th, 2025 7:30 am
NovoCure (NVCR) Reports Q1 Loss, Tops Revenue Estimates - Apr 24th, 2025 6:15 am
NovoCure: Q1 Earnings Snapshot - Apr 24th, 2025 5:13 am
Novocure Reports First Quarter 2025 Financial Results - Apr 24th, 2025 5:00 am
Novocure to Present Results from the Phase 3 PANOVA-3 Clinical Trial of its Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer as a Late-Breaking Oral Presentation at the 2025 ASCO Annual Meeting - Apr 23rd, 2025 8:16 am
Novocure’s device for metastatic NSCLC treatment gains CE Mark - Apr 23rd, 2025 4:45 am